PARADIGM, a pivotal multicenter study, evaluates the company’s Endoluminal Surgical (ELS) system. It looks at ELS in lower gastrointestinal (GI) tract procedures by both colorectal surgeons and gastroenterologists.

In May, the company announced the first colorectal cases in the trial. The latest procedures mark the world’s first fully robotic endoscopic submucosal dissection (ESD) performed by a gastroenterologist in an FDA investigational device exemption (IDE) pivotal trial. The FDA granted the IDE for the study last December.